Dudediligence.

Arcturus Therapeutics Holdings Inc

ARCTNASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$41.7MSep ’24$22.8MDec ’24$29.4MMar ’25$28.3MJun ’25$17.2MSep ’25$7.2MDec ’25$2.1MMar ’26$3.0MJun ’26
Net income, by quarter
−$6.9MSep ’24−$30.0MDec ’24−$14.1MMar ’25−$9.2MJun ’25−$13.4MSep ’25−$29.1MDec ’25−$27.0MMar ’26−$23.8MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$12.4M$206.0M$166.8M$152.3M$82.0M
Operating income−$202.9M$12.2M−$78.2M−$95.7M−$76.3M
Net income−$203.7M$9.3M−$29.7M−$80.9M−$65.8M
Operating cash flow−$135.0M$32.0M−$18.1M−$59.7M−$74.3M
Free cash flow−$138.4M$24.3M−$21.0M−$60.4M−$74.5M
Cash$370.5M$391.9M$292.0M$237.0M$230.9M
Debt$63.1M$60.7Mnone on filenone on filenone on file
Shares outstanding26.4M26.6M26.8M27.0M28.4M